- Conditions
- Non-small Cell Lung Cancer, Carcinoma, NSCLC
- Interventions
- Ensartinib, Durvalumab
- Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bioequivalency
- Interventions
- Ensartinib Hydrochloride
- Drug
- Lead sponsor
- Xcovery Holdings, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Advanced Solid Tumors, Non-small Cell Lung Cancer
- Interventions
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Drug
- Lead sponsor
- Xcovery Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 14
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 10 more